These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Neurofibroma with increased uptake of [F-18]-fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion. Hsu CH; Lee CM; Wang FC; Fang CL Ann Nucl Med; 2003 Oct; 17(7):609-11. PubMed ID: 14651363 [TBL] [Abstract][Full Text] [Related]
23. [Rapid diagnosis of recurrence of a tall cell variant of papillary thyroid cancer by endogenous TSH stimulation]. Görges R; Liedke MO; Worm K; Frilling A; Bockisch A; Schmid KW Nuklearmedizin; 2003 Jun; 42(3):N15-8. PubMed ID: 12848153 [No Abstract] [Full Text] [Related]
24. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. Laking GR; Price PM J Nucl Med; 2002 Dec; 43(12):1728-9; author reply 1729. PubMed ID: 12468527 [No Abstract] [Full Text] [Related]
27. F-18 fluorodeoxyglucose accumulation in an inflammatory pseudotumor of the spleen. Sato M; Takasaka I; Okumura T; Shioyama Y; Asato Y; Yoshimi F; Imura J; Amemiya R Ann Nucl Med; 2007 Nov; 21(9):521-4. PubMed ID: 18030584 [TBL] [Abstract][Full Text] [Related]
28. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. Gordon BA; Flanagan FL; Dehdashti F AJR Am J Roentgenol; 1997 Dec; 169(6):1675-80. PubMed ID: 9393189 [No Abstract] [Full Text] [Related]
29. [Primary diagnosis of papillary thyroid carcinoma in the framework of staging of malignant melanoma with F-18 deoxyglucose using PET]. Menzel C; Risse JH; Biersack HJ; Grünwald F Nuklearmedizin; 2001 Jun; 40(3):N23-4. PubMed ID: 11475082 [No Abstract] [Full Text] [Related]
30. PET image acquisition and analysis. Votaw JR Adv Neurol; 2000; 83():69-86. PubMed ID: 10999190 [No Abstract] [Full Text] [Related]
31. [Granulation tissue: pitfall in therapy control with F-18-FDG PET after chemotherapy]. Lorenzen J; de Wit M; Buchert R; Igel B; Bohuslavizki KH Nuklearmedizin; 1999; 38(8):333-6. PubMed ID: 10615668 [TBL] [Abstract][Full Text] [Related]
32. Intense FDG uptake in a benign Hurthle cell adenoma. Rohren EM Clin Nucl Med; 2004 Oct; 29(10):664-6. PubMed ID: 15365450 [No Abstract] [Full Text] [Related]
33. Focal F-18 fluorodexyglucose positron emission tomography uptake in a hyalinized nodule as a false positive splenic metastasis in a patient with breast cancer and metastatic thyroid cancer. Choi AY; Wax BN; Yung E Clin Nucl Med; 2005 Dec; 30(12):799-800. PubMed ID: 16319637 [No Abstract] [Full Text] [Related]
34. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Salvatori M; Melis L; Castaldi P; Maussier ML; Rufini V; Perotti G; Rubello D Biomed Pharmacother; 2007 Sep; 61(8):488-93. PubMed ID: 17604940 [TBL] [Abstract][Full Text] [Related]
35. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Kresnik E; Gallowitsch HJ; Mikosch P; Stettner H; Igerc I; Gomez I; Kumnig G; Lind P Surgery; 2003 Mar; 133(3):294-9. PubMed ID: 12660642 [TBL] [Abstract][Full Text] [Related]
36. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980 [TBL] [Abstract][Full Text] [Related]